Portage Biotech Inc. approved a director compensation plan on March 7, 2025, which includes an annual cash fee of $30,000 for directors and a one-time fee of $25,000 upon completion of a reverse merger. Additionally, 160,000 options were granted for ordinary shares at $4.45 each, with specific vesting terms.